Click for best price
Drugs for Metabolic Disorders Market Size, Share 2024
| Market size in 2023 |
US$ 77480 million
|
Forecast Market size by 2030 |
US$ 156290 million
|
| Growth Rate |
CAGR of 10.6% |
Number of Pages |
118 Pages |
This research report provides a comprehensive analysis of the Drugs for Metabolic Disorders market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Drugs for Metabolic Disorders market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Drugs for Metabolic Disorders, challenges faced by the industry, and potential opportunities for market players.
The global Drugs for Metabolic Disorders market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Drugs for Metabolic Disorders market presents opportunities for various stakeholders, including Hospital, Retail Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Drugs for Metabolic Disorders market. Additionally, the growing consumer demand present avenues for market expansion.
The global Drugs for Metabolic Disorders market was valued at US$ 77480 million in 2023 and is projected to reach US$ 156290 million by 2030, at a CAGR of 10.6% during the forecast period.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.
Key Features:
The research report on the Drugs for Metabolic Disorders market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Drugs for Metabolic Disorders market.
Market Overview: The report provides a comprehensive overview of the Drugs for Metabolic Disorders market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Drugs for Metabolic Disorders market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Drugs for Metabolic Disorders market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Drugs for Metabolic Disorders market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Drugs for Metabolic Disorders market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Drugs for Metabolic Disorders market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Drugs for Metabolic Disorders market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Drugs for Metabolic Disorders, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Drugs for Metabolic Disorders market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
- Drugs for Metabolic Disorders market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Glycogen Metabolism Disease Drug
- Lipid Metabolism Disease Drug
- Amino Acid Metabolism Drug
- Other
Market segment by Application
Global Drugs for Metabolic Disorders Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Merck
- Novartis
- Takeda Pharmaceutical
- Astra Zeneca
- Boehringer Ingelheim
- KOWA
- Kythera
- Fuji yakuhin
- LG Life Science
- Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Metabolic Disorders, market overview.
Chapter 2: Global Drugs for Metabolic Disorders market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Metabolic Disorders manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Metabolic Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Metabolic Disorders capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Drugs for Metabolic Disorders Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 77480 million
|
| Forecast Market size by 2030 |
US$ 156290 million
|
| Growth Rate |
CAGR of 10.6% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
118 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Metabolic Disorders Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Metabolic Disorders Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Metabolic Disorders Overall Market Size
2.1 Global Drugs for Metabolic Disorders Market Size: 2023 VS 2030
2.2 Global Drugs for Metabolic Disorders Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Drugs for Metabolic Disorders Sales: 2019-2030
3 Company Landscape
3.1 Top Drugs for Metabolic Disorders Players in Global Market
3.2 Top Global Drugs for Metabolic Disorders Companies Ranked by Revenue
3.3 Global Drugs for Metabolic Disorders Revenue by Companies
3.4 Global Drugs for Metabolic Disorders Sales by Companies
3.5 Global Drugs for Metabolic Disorders Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Drugs for Metabolic Disorders Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Drugs for Metabolic Disorders Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Metabolic Disorders Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Metabolic Disorders Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Metabolic Disorders Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Metabolic Disorders Market Size Markets, 2023 & 2030
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type - Global Drugs for Metabolic Disorders Revenue & Forecasts
4.2.1 By Type - Global Drugs for Metabolic Disorders Revenue, 2019-2024
4.2.2 By Type - Global Drugs for Metabolic Disorders Revenue, 2025-2030
4.2.3 By Type - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
4.3 By Type - Global Drugs for Metabolic Disorders Sales & Forecasts
4.3.1 By Type - Global Drugs for Metabolic Disorders Sales, 2019-2024
4.3.2 By Type - Global Drugs for Metabolic Disorders Sales, 2025-2030
4.3.3 By Type - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
4.4 By Type - Global Drugs for Metabolic Disorders Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Metabolic Disorders Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application - Global Drugs for Metabolic Disorders Revenue & Forecasts
5.2.1 By Application - Global Drugs for Metabolic Disorders Revenue, 2019-2024
5.2.2 By Application - Global Drugs for Metabolic Disorders Revenue, 2025-2030
5.2.3 By Application - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
5.3 By Application - Global Drugs for Metabolic Disorders Sales & Forecasts
5.3.1 By Application - Global Drugs for Metabolic Disorders Sales, 2019-2024
5.3.2 By Application - Global Drugs for Metabolic Disorders Sales, 2025-2030
5.3.3 By Application - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
5.4 By Application - Global Drugs for Metabolic Disorders Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Drugs for Metabolic Disorders Market Size, 2023 & 2030
6.2 By Region - Global Drugs for Metabolic Disorders Revenue & Forecasts
6.2.1 By Region - Global Drugs for Metabolic Disorders Revenue, 2019-2024
6.2.2 By Region - Global Drugs for Metabolic Disorders Revenue, 2025-2030
6.2.3 By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
6.3 By Region - Global Drugs for Metabolic Disorders Sales & Forecasts
6.3.1 By Region - Global Drugs for Metabolic Disorders Sales, 2019-2024
6.3.2 By Region - Global Drugs for Metabolic Disorders Sales, 2025-2030
6.3.3 By Region - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Drugs for Metabolic Disorders Revenue, 2019-2030
6.4.2 By Country - North America Drugs for Metabolic Disorders Sales, 2019-2030
6.4.3 US Drugs for Metabolic Disorders Market Size, 2019-2030
6.4.4 Canada Drugs for Metabolic Disorders Market Size, 2019-2030
6.4.5 Mexico Drugs for Metabolic Disorders Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Drugs for Metabolic Disorders Revenue, 2019-2030
6.5.2 By Country - Europe Drugs for Metabolic Disorders Sales, 2019-2030
6.5.3 Germany Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.4 France Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.5 U.K. Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.6 Italy Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.7 Russia Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.8 Nordic Countries Drugs for Metabolic Disorders Market Size, 2019-2030
6.5.9 Benelux Drugs for Metabolic Disorders Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Drugs for Metabolic Disorders Revenue, 2019-2030
6.6.2 By Region - Asia Drugs for Metabolic Disorders Sales, 2019-2030
6.6.3 China Drugs for Metabolic Disorders Market Size, 2019-2030
6.6.4 Japan Drugs for Metabolic Disorders Market Size, 2019-2030
6.6.5 South Korea Drugs for Metabolic Disorders Market Size, 2019-2030
6.6.6 Southeast Asia Drugs for Metabolic Disorders Market Size, 2019-2030
6.6.7 India Drugs for Metabolic Disorders Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Drugs for Metabolic Disorders Revenue, 2019-2030
6.7.2 By Country - South America Drugs for Metabolic Disorders Sales, 2019-2030
6.7.3 Brazil Drugs for Metabolic Disorders Market Size, 2019-2030
6.7.4 Argentina Drugs for Metabolic Disorders Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, 2019-2030
6.8.3 Turkey Drugs for Metabolic Disorders Market Size, 2019-2030
6.8.4 Israel Drugs for Metabolic Disorders Market Size, 2019-2030
6.8.5 Saudi Arabia Drugs for Metabolic Disorders Market Size, 2019-2030
6.8.6 UAE Drugs for Metabolic Disorders Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Drugs for Metabolic Disorders Major Product Offerings
7.1.4 Merck Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Drugs for Metabolic Disorders Major Product Offerings
7.2.4 Novartis Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Major Product Offerings
7.3.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Drugs for Metabolic Disorders Major Product Offerings
7.4.4 Astra Zeneca Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Drugs for Metabolic Disorders Major Product Offerings
7.5.4 Boehringer Ingelheim Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Drugs for Metabolic Disorders Major Product Offerings
7.6.4 KOWA Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Drugs for Metabolic Disorders Major Product Offerings
7.7.4 Kythera Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Drugs for Metabolic Disorders Major Product Offerings
7.8.4 Fuji yakuhin Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Drugs for Metabolic Disorders Major Product Offerings
7.9.4 LG Life Science Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales and Revenue in Global (2019-2024)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Global Drugs for Metabolic Disorders Production Capacity, Analysis
8.1 Global Drugs for Metabolic Disorders Production Capacity, 2019-2030
8.2 Drugs for Metabolic Disorders Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Metabolic Disorders Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Metabolic Disorders Supply Chain Analysis
10.1 Drugs for Metabolic Disorders Industry Value Chain
10.2 Drugs for Metabolic Disorders Upstream Market
10.3 Drugs for Metabolic Disorders Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Metabolic Disorders Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Drugs for Metabolic Disorders in Global Market
Table 2. Top Drugs for Metabolic Disorders Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Drugs for Metabolic Disorders Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Drugs for Metabolic Disorders Revenue Share by Companies, 2019-2024
Table 5. Global Drugs for Metabolic Disorders Sales by Companies, (K Units), 2019-2024
Table 6. Global Drugs for Metabolic Disorders Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Drugs for Metabolic Disorders Price (2019-2024) & (USD/Unit)
Table 8. Global Manufacturers Drugs for Metabolic Disorders Product Type
Table 9. List of Global Tier 1 Drugs for Metabolic Disorders Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Metabolic Disorders Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Drugs for Metabolic Disorders Sales (K Units), 2019-2024
Table 15. By Type - Global Drugs for Metabolic Disorders Sales (K Units), 2025-2030
Table 16. By Application ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Drugs for Metabolic Disorders Sales (K Units), 2019-2024
Table 20. By Application - Global Drugs for Metabolic Disorders Sales (K Units), 2025-2030
Table 21. By Region ? Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Drugs for Metabolic Disorders Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Drugs for Metabolic Disorders Sales (K Units), 2019-2024
Table 25. By Region - Global Drugs for Metabolic Disorders Sales (K Units), 2025-2030
Table 26. By Country - North America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Drugs for Metabolic Disorders Sales, (K Units), 2019-2024
Table 29. By Country - North America Drugs for Metabolic Disorders Sales, (K Units), 2025-2030
Table 30. By Country - Europe Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Drugs for Metabolic Disorders Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Drugs for Metabolic Disorders Sales, (K Units), 2019-2024
Table 33. By Country - Europe Drugs for Metabolic Disorders Sales, (K Units), 2025-2030
Table 34. By Region - Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Drugs for Metabolic Disorders Sales, (K Units), 2019-2024
Table 37. By Region - Asia Drugs for Metabolic Disorders Sales, (K Units), 2025-2030
Table 38. By Country - South America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Drugs for Metabolic Disorders Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Drugs for Metabolic Disorders Sales, (K Units), 2019-2024
Table 41. By Country - South America Drugs for Metabolic Disorders Sales, (K Units), 2025-2030
Table 42. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, (K Units), 2019-2024
Table 45. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales, (K Units), 2025-2030
Table 46. Merck Company Summary
Table 47. Merck Drugs for Metabolic Disorders Product Offerings
Table 48. Merck Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 49. Merck Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Drugs for Metabolic Disorders Product Offerings
Table 52. Novartis Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 53. Novartis Key News & Latest Developments
Table 54. Takeda Pharmaceutical Company Summary
Table 55. Takeda Pharmaceutical Drugs for Metabolic Disorders Product Offerings
Table 56. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 57. Takeda Pharmaceutical Key News & Latest Developments
Table 58. Astra Zeneca Company Summary
Table 59. Astra Zeneca Drugs for Metabolic Disorders Product Offerings
Table 60. Astra Zeneca Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 61. Astra Zeneca Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Drugs for Metabolic Disorders Product Offerings
Table 64. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. KOWA Company Summary
Table 67. KOWA Drugs for Metabolic Disorders Product Offerings
Table 68. KOWA Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 69. KOWA Key News & Latest Developments
Table 70. Kythera Company Summary
Table 71. Kythera Drugs for Metabolic Disorders Product Offerings
Table 72. Kythera Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 73. Kythera Key News & Latest Developments
Table 74. Fuji yakuhin Company Summary
Table 75. Fuji yakuhin Drugs for Metabolic Disorders Product Offerings
Table 76. Fuji yakuhin Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 77. Fuji yakuhin Key News & Latest Developments
Table 78. LG Life Science Company Summary
Table 79. LG Life Science Drugs for Metabolic Disorders Product Offerings
Table 80. LG Life Science Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 81. LG Life Science Key News & Latest Developments
Table 82. Metsubishi Tanabe Pharma Company Summary
Table 83. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Offerings
Table 84. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2019-2024)
Table 85. Metsubishi Tanabe Pharma Key News & Latest Developments
Table 86. Drugs for Metabolic Disorders Production Capacity (K Units) of Key Manufacturers in Global Market, 2022-2024 (K Units)
Table 87. Global Drugs for Metabolic Disorders Capacity Market Share of Key Manufacturers, 2022-2024
Table 88. Global Drugs for Metabolic Disorders Production by Region, 2019-2024 (K Units)
Table 89. Global Drugs for Metabolic Disorders Production by Region, 2025-2030 (K Units)
Table 90. Drugs for Metabolic Disorders Market Opportunities & Trends in Global Market
Table 91. Drugs for Metabolic Disorders Market Drivers in Global Market
Table 92. Drugs for Metabolic Disorders Market Restraints in Global Market
Table 93. Drugs for Metabolic Disorders Raw Materials
Table 94. Drugs for Metabolic Disorders Raw Materials Suppliers in Global Market
Table 95. Typical Drugs for Metabolic Disorders Downstream
Table 96. Drugs for Metabolic Disorders Downstream Clients in Global Market
Table 97. Drugs for Metabolic Disorders Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Metabolic Disorders Segment by Type in 2023
Figure 2. Drugs for Metabolic Disorders Segment by Application in 2023
Figure 3. Global Drugs for Metabolic Disorders Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Drugs for Metabolic Disorders Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Metabolic Disorders Revenue, 2019-2030 (US$, Mn)
Figure 7. Drugs for Metabolic Disorders Sales in Global Market: 2019-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Metabolic Disorders Revenue in 2023
Figure 9. By Type - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 11. By Type - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 12. By Type - Global Drugs for Metabolic Disorders Price (USD/Unit), 2019-2030
Figure 13. By Application - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 15. By Application - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 16. By Application - Global Drugs for Metabolic Disorders Price (USD/Unit), 2019-2030
Figure 17. By Region - Global Drugs for Metabolic Disorders Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 20. By Region - Global Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 21. By Country - North America Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 22. By Country - North America Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 23. US Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 28. Germany Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 29. France Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 37. China Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 41. India Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 43. By Country - South America Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 44. Brazil Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Drugs for Metabolic Disorders Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Drugs for Metabolic Disorders Sales Market Share, 2019-2030
Figure 48. Turkey Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Drugs for Metabolic Disorders Revenue, (US$, Mn), 2019-2030
Figure 52. Global Drugs for Metabolic Disorders Production Capacity (K Units), 2019-2030
Figure 53. The Percentage of Production Drugs for Metabolic Disorders by Region, 2023 VS 2030
Figure 54. Drugs for Metabolic Disorders Industry Value Chain
Figure 55. Marketing Channels
